Nuclear export inhibitors with anti-tumoral and anti-viral activity
Regulated nucleo-cytoplasmic transport of pathobiologically relevant proteins is critical for tumor development and viral diseases. Transport is mediated by nuclear export signals (NESs) interacting with the export receptor CRM1. NESs have been identified in numerous disease relevant cellular and viral proteins. Hence, the pharmacogenetic interference with nuclear export provides an attractive and novel therapeutic principle to rationally control and target the activity of such disease factors. This invention now provides three novel nuclear export inhibitors (NEIs) with shown anti-tumoral and antiviral activity. As such, these drugs may represent a hitherto neglected additional pillar for combination treatment of human diseases.
Further Information: PDF
IMG Innovations-Management GmbH
Phone: +49 (0)631/31668-50
Contact
Dr. Klaus Kobek
Media Contact
All latest news from the category: Technology Offerings
Newest articles
Innovative 3D printed scaffolds offer new hope for bone healing
Researchers at the Institute for Bioengineering of Catalonia have developed novel 3D printed PLA-CaP scaffolds that promote blood vessel formation, ensuring better healing and regeneration of bone tissue. Bone is…
The surprising role of gut infection in Alzheimer’s disease
ASU- and Banner Alzheimer’s Institute-led study implicates link between a common virus and the disease, which travels from the gut to the brain and may be a target for antiviral…
Molecular gardening: New enzymes discovered for protein modification pruning
How deubiquitinases USP53 and USP54 cleave long polyubiquitin chains and how the former is linked to liver disease in children. Deubiquitinases (DUBs) are enzymes used by cells to trim protein…